Victory Capital Management
ZYNE

Victory Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Victory Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,346
Closed -$24K – 3467
2020
Q1 		$24K Buy
+6,346
New +$29.5K ﹤0.01% 3044
2019
Q4 		– Sell
-3,915
Closed -$30K – 3453
2019
Q3 		$30K Buy
+3,915
New +$44.1K ﹤0.01% 2909

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Victory Capital Management's ZYNE Position: Q2 2020 in Review

Victory Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2020, closing a stake of 6,346 shares — an estimated $24K sold.

Victory Capital Management first reported a position in ZYNE in Q3 2019 and held it in 2 quarters. The position peaked at $30K in Q3 2019. 74 funds tracked by Wall St. Rank hold ZYNE as of Q2 2020.

  • Victory Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 6,346 Zynerba Pharmaceuticals, Inc shares in Q2 2020, an estimated $24K.
  • Victory Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $30K in Q3 2019.
  • 74 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.